Specifically, results of previous studies suggest that patients with high grade serous ovarian cancer and either BRCA1 or BRCA2 mutations have different clinicopathological features, response to treatment, and prognosis [14,15]. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.